Abstract
Goal The COVID-19 pandemic has emerged as the most severe public health crisis in over a century. As of January 2021, there are more than 100 million cases and 2.1 million deaths. For informed decision making, reliable statistical data and capable simulation tools are needed. Our goal is to develop an epidemic simulator that can model the effects of random population testing and contact tracing.
Methods Our simulator models individuals as particles with the position, velocity, and epidemic status states on a 2D map and runs an SEIR epidemic model with contact tracing and testing modules. The simulator is available on GitHub under the MIT license.
Results The results show that the synergistic use of contact tracing and massive testing is effective in suppressing the epidemic (the number of deaths was reduced by 72%).
Conclusions The Particle-based COVID-19 simulator enables the modeling of intervention measures, random testing, and contact tracing, for epidemic mitigation and suppression.
Impact Statement Our particle-based epidemic simulator, calibrated with COVID-19 data, models each individual as a unique particle with a location, velocity, and epidemic state, enabling the consideration of contact tracing and testing measures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work did not require IRB approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
As supplementary materials, we provide the source code of the simulator, equations for the transitions between the epidemic states, and a video that illustrates the effectiveness of using random testing and contact tracing strategies.
https://www.youtube.com/watch?v=BJfjmWfi6ac&feature=youtu.be
